Vaxcyte, Inc. (PCVX)
NASDAQ: PCVX · Real-Time Price · USD
55.96
+2.98 (5.62%)
Jul 30, 2026, 4:00 PM EDT - Market closed
Vaxcyte Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 260.84 | 173.96 | 387.88 | 397.45 | 834.66 | 68.99 |
Short-Term Investments | 1,476 | 1,387 | 1,359 | 682.78 | 96.72 | 176.99 |
Cash & Short-Term Investments | 1,737 | 1,561 | 1,747 | 1,080 | 931.38 | 245.97 |
Cash Growth | 3.91% | -10.66% | 61.75% | 15.98% | 278.65% | -36.31% |
Other Current Assets | 76.31 | 66.4 | 40.78 | 15.73 | 11.18 | 10.38 |
Total Current Assets | 1,813 | 1,627 | 1,788 | 1,096 | 942.56 | 256.35 |
Net Property, Plant & Equipment | 373.8 | 373.38 | 270.15 | 110.62 | 31.65 | 35.91 |
Long-Term Investments | 1,004 | 881.66 | 1,388 | 162.68 | 26.55 | 27.12 |
Other Long-Term Assets | 157.01 | 120.31 | 65.68 | 38.67 | 5.43 | 4.96 |
Total Assets | 3,348 | 3,003 | 3,511 | 1,408 | 1,006 | 324.34 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 63.06 | 70.9 | 48.45 | 14.59 | 9.8 | 6.76 |
Accrued Expenses | 172.94 | 128.72 | 85.84 | 123.64 | 24.82 | 16.68 |
Current Portion of Leases | 6.09 | 6.12 | 5.89 | 7.11 | 5.91 | 5.28 |
Total Current Liabilities | 242.08 | 205.75 | 140.18 | 145.34 | 40.53 | 28.72 |
Long-Term Leases | 110.21 | 111.36 | 65.22 | 22.11 | 12.03 | 11.51 |
Other Long-Term Liabilities | - | 0.1 | 0.1 | - | 0.01 | 0.1 |
Total Long-Term Liabilities | 110.21 | 111.46 | 65.32 | 22.11 | 12.04 | 11.6 |
Total Liabilities | 352.29 | 317.21 | 205.5 | 167.45 | 52.57 | 40.32 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.15 | 0.13 | 0.13 | 0.1 | 0.08 | 0.06 |
Additional Paid-in Capital | 5,478 | 4,839 | 4,698 | 2,165 | 1,476 | 582.84 |
Accumulated Other Comprehensive Income | -6.83 | 1.59 | -3.87 | 0.18 | -0.36 | -0.24 |
Retained Earnings | -2,476 | -2,155 | -1,388 | -924.39 | -522.13 | -298.64 |
Shareholders' Equity | 2,996 | 2,686 | 3,306 | 1,240 | 953.61 | 284.02 |
Total Liabilities & Equity | 3,348 | 3,003 | 3,511 | 1,408 | 1,006 | 324.34 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 116.3 | 117.48 | 71.11 | 29.22 | 17.94 | 16.78 |
Net Cash (Debt) | 1,621 | 1,443 | 1,676 | 1,051 | 913.44 | 229.19 |
Net Cash Growth | 2.30% | -13.88% | 59.48% | 15.06% | 298.55% | -40.65% |
Net Cash Per Share | 11.83 | 10.61 | 13.74 | 10.82 | 14.08 | 4.41 |
Book Value | 2,996 | 2,686 | 3,306 | 1,240 | 953.61 | 284.02 |
Book Value Per Share | 21.86 | 19.73 | 27.10 | 12.77 | 14.70 | 5.47 |
Tangible Book Value | 2,996 | 2,686 | 3,306 | 1,240 | 953.61 | 284.02 |
Tangible Book Value Per Share | 21.86 | 19.73 | 27.10 | 12.77 | 14.70 | 5.47 |